B cell–directed therapies effective in CAD
| Study/publication reference . | Drug(s) studied . | Study design . | Patients/courses of therapy, n . | OR, % . | CR, % . | Hb increase, g/dL* . | Median response duration, mo . | Toxicity† . |
|---|---|---|---|---|---|---|---|---|
| 30 | Rituximab | Prospective, nonrandomized | 27/37 | 54 | 4 | 4.0 | 11 (observed) | Low |
| 12 | Rituximab | Prospective, nonrandomized | 20/20 | 45 | 5 | 3.1 | 6.5 (observed) | Low |
| 52 | Fludarabine + rituximab | Prospective, nonrandomized | 29/29 | 76 | 21 | 3.1 | >66 (estimated) | Significant |
| 43 | Bendamustine + rituximab | Prospective, nonrandomized | 45/45 | 71 | 40 | 4.0 | >32 (observed) | Relatively low, manageable |
| 53 | Bortezomib | Prospective, nonrandomized | 19/19 | 32 | 16 | 2.9 | 16 (observed) | Low |
| 1 | Bendamustine + rituximab | Follow-up, part of larger study | 45/45 | 78 | 53 | Not reevaluated | >88 (estimated) | Long-term: low |
| Study/publication reference . | Drug(s) studied . | Study design . | Patients/courses of therapy, n . | OR, % . | CR, % . | Hb increase, g/dL* . | Median response duration, mo . | Toxicity† . |
|---|---|---|---|---|---|---|---|---|
| 30 | Rituximab | Prospective, nonrandomized | 27/37 | 54 | 4 | 4.0 | 11 (observed) | Low |
| 12 | Rituximab | Prospective, nonrandomized | 20/20 | 45 | 5 | 3.1 | 6.5 (observed) | Low |
| 52 | Fludarabine + rituximab | Prospective, nonrandomized | 29/29 | 76 | 21 | 3.1 | >66 (estimated) | Significant |
| 43 | Bendamustine + rituximab | Prospective, nonrandomized | 45/45 | 71 | 40 | 4.0 | >32 (observed) | Relatively low, manageable |
| 53 | Bortezomib | Prospective, nonrandomized | 19/19 | 32 | 16 | 2.9 | 16 (observed) | Low |
| 1 | Bendamustine + rituximab | Follow-up, part of larger study | 45/45 | 78 | 53 | Not reevaluated | >88 (estimated) | Long-term: low |